Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

Hohnloser, Stefan H.; Zabel, Markus

doi:10.1016/0002-9149(92)91071-b

Cited by 74Cardiac Arrhythmias and TreatmentsAtrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

Hohnloser, Stefan H., Zabel, Markus·1992·The American Journal of Cardiology

DOI 10.1016/0002-9149(92)91071-b

Open this paper in CoChat — free account

Abstract

This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias. For this purpose, 60 original articles were identified by a literature search representing data from 1,835 treatment courses. In 18 trials, flecainide was administered intravenously; in 19, orally; and in 23, both forms of therapy were applied. There were 5 placebo-controlled and 12 comparative studies, whereas data from uncontrolled studies were represented in 43 articles. Short-term flecainide administration terminated atrial fibrillation in 65% of attempts and terminated atrial flutter in 28%. The drug was effective during long-term therapy for atrial fibrillation in 49% of patients, with similar efficacy rates in 11 comparative trials and in 16 uncontrolled studies. In randomized, placebo-controlled studies in patients with paroxysmal atrial fibrillation, flecainide was shown to reduce significantly the number of attacks, to prolong the time between attacks, and to improve quality of life. In patients with atrioventricular (AV) reciprocating tachycardias, acute drug administration was successful in 72%; 83% of patients with AV nodal reentrant tachycardias and 74% exhibiting arrhythmias associated with the Wolff-Parkinson-White syndrome responded acutely. During long-term therapy, efficacy rates were 70%, 78%, and 69%, respectively. Ectopic atrial tachycardia responded in 86% and 95% of patients treated with flecainide acutely or chronically. Data concerning drug-related side effects were available for 1,794 of 1,835 treatment courses (98%). Overall, 352 of 1,794 patients (20%) reported at least one non-cardiac or cardiac adverse experience.(ABSTRACT TRUNCATED AT 250 WORDS)

Integrity signals

Registry

Crossref · 10.1016/0002-9149(92)91071-b

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Class Ia, Ic, and III drugs may work by prolonging the action potential or suppressing automaticity.
“Class Ia, Ic, and III drugs may work as well, by prolonging the action potential or suppressing automaticity.107,108,110”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [107]
Class Ia, Ic, and III drugs may be effective for chronic AT if first-line therapy failed, but Ia and Ic agents should ideally be combined with AV node blocking agents.
“Class Ia, Ic, and III drugs may be effective if first-line therapy has failed, but Ia and Ic agents should be ideally combined associated with AV node blocking agents.107 -109,115,116”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [107]

Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,244 · see citing works
Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current
Jackman, W. M., Wang, X., Friday, K. J., Roman, C. A., Moulton, K. P., Beckman, K. J., McClelland, J. H., Twidale, N., Hazlitt, H. A., Prior, M. I., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242301 · Cited by 1,422 · see citing works
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 944 · see citing works
Diagnosis and Cure of the Wolff–Parkinson–White Syndrome or Paroxysmal Supraventricular Tachycardias during a Single Electrophysiologic Test
Calkins, H. G., de Sousa, J., El-Atassi, R., Rosenheck, S., de Buitleir, M., Kou, W. H., Kadish, A. H., Langberg, J. J., & Morady, F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242302 · Cited by 698 · see citing works
Quinidine Syncope
Selzer, A., & WRAY, H. W. (1964) · Circulation · doi:10.1161/01.cir.30.1.17 · Cited by 564 · see citing works
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. C. (1989) · Circulation · doi:10.1161/01.cir.80.6.1557 · Cited by 287 · see citing works
High frequency alternating current ablation of an accessory pathway in humans
Borggrefe, M., Budde, T., Podczeck, A., & Breithardt, G. (1987) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(87)80200-0 · Cited by 285 · see citing works
The Cardiac Arrhythmia Suppression Trial (CAST)
Ruskin, J. N. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210608 · Cited by 234 · see citing works
Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
SUTTORP, M. J., Kingma, J. H., Lie‐A‐Huen, L., & Mast, E. G. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90253-1 · Cited by 176 · see citing works
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
Henthorn, R. W., Waldo, A. L., Anderson, J. L., Gilbert, E. M., Alpert, B. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. C. (1991) · Circulation · doi:10.1161/01.cir.83.1.119 · Cited by 96 · see citing works
The status of surgery for cardiac arrhythmias.
Cox, J. L. (1985) · Circulation · doi:10.1161/01.cir.71.3.413 · Cited by 82 · see citing works
Summary of efficacy and safety of flecainide for supraventricular arrhythmias
Anderson, J. L., Jolivette, D. M., & Fredell, P. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90511-5 · Cited by 79 · see citing works
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies
Pritchett, E. L. C., DaTorre, S. D., Platt, M., McCarville, S., & Hougham, A. J. (1991) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80090-7 · Cited by 75 · see citing works
Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias
Pritchett, E. L. C., & Wilkinson, W. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90170-p · Cited by 67 · see citing works
Atrial Flutter, Atrial Fibrillation, and Other Primary Atrial Tachycardias
Benditt, D. G., Benson, D. W., Dunnigan, A., Gornick, C. C., & Anderson, R. W. (1984) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31105-1 · Cited by 59 · see citing works
Ablation of a Left‐Sided Free‐Wall Accessory Pathway by Percutaneous Catheter Application of Radiofrequency Current in a Patient with the Wolff‐Parkinson‐White Syndrome
Kück, K., Kunze, K.-P., Schlüter, M., GEICER, M., & Jackman, W. M. (1989) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1989.tb01847.x · Cited by 51 · see citing works
Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia
Pritchett, E. L. C., Hammill, S. C., Reiter, M. J., Lee, K. L., McCarthy, E. A., Zimmerman, J. M., & Shand, D. G. (1983) · The American Journal of Cardiology · doi:10.1016/0002-9149(83)90521-0 · Cited by 44 · see citing works
Flecainide acetate in atrial flutter and fibrillation
Sihm, I., HANSEN, F. A., RASMUSSEN, J., Pedersen, A. K., & Thygesen, K. A. (1990) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059670 · Cited by 44 · see citing works
Implanted Atrial Pacemakers for Paroxysmal Atrial Flutter
Barold, S. S., WYNDHAM, C. R. C., KAPPENBERGER, L. L., ABINADER, E. G., Griffin, J. C., & FALKOFF, M. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-144 · Cited by 37 · see citing works
The Cardiac Arrhythmia Suppression Trial
(1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212510 · Cited by 32 · see citing works
Prophylactic treatment after electroconversion of atrial fibrillation
Karlson, B. W., Herlitz, J. D., Edvardsson, N. G., & Olsson, S. B. (1990) · Clinical Cardiology · doi:10.1002/clc.4960130409 · Cited by 23 · see citing works
Therapie des paroxysmalen Vorhofflimmerns: Herzglykoside allein oder in Kombination mit Antiarrhythmika?*
Steinbeck, G., Doliwa, R., & Bach, P. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1067903 · Cited by 18 · see citing works
Current clinical perspectives on antiarrhythmic drug therapy.
Jl, A. (1986) · PubMed · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)
Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomström‐Lundqvist, C., Calkins, H. G., Corrado, D., Deftereos, S. G., Diller, G., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz467 · Cited by 1,278 · see citing works
Untitled work
Blomstrom-Lundqvist (2003) · doi:10.1161/01.cir.0000091380.04100.84 · Cited by 955 · see citing works
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias∗∗This document does not cover atrial fibrillation; atrial fibrillation is covered in the ACC/AHA/ESC guidelines on the management of patients with atrial fibrillation found on the ACC, AHA, and ESC Web sites.—executive summary
Blomström‐Lundqvist, C., Scheinman, M. M., Aliot, E., Alpert, J. S., Calkins, H. G., Camm, A. J., Campbell, W. B., Haines, D. E., Kück, K., Lerman, B. B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.013 · Cited by 681 · see citing works
Inpatient general medicine is evidence based
Sackett, D. L., Ellis, J., Mulligan, I., & Rowe, J. B. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92781-6 · Cited by 433 · see citing works
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Tamargo, J. L., Heuzey, J. L., & Mabo, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1832-0 · Cited by 279 · see citing works
Meta-analysis of ablation of atrial flutter and supraventricular tachycardia
Spector, P., Reynolds, M. R., Calkins, H., Sondhi, M., Xu, Y., Martin, A., Williams, C. J., & Sledge, I. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.040 · Cited by 268 · see citing works
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary
Blomström‐Lundqvist, C., Scheinman, M. M., Aliot, E., Alpert, J. S., Calkins, H., Camm, A. J., Campbell, W. B., Haines, D. E., Kück, K., Lerman, B. B., et al. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.002 · Cited by 266 · see citing works
European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)
Katritsis, D. G., Boriani, G., Cosio, F. G., Hindricks, G., Jaïs, P., Josephson, M. E., Keegan, R., Kim, Y.-H., Knight, B. P., Kuck, K.-H., et al. (2017) · Europace · doi:10.1093/europace/euw301 · Cited by 188 · see citing works
“Meta-Analysis of Ablation of Atrial Flutter and Supraventricular Tachycardia”
Navarese, E. P., Lupi, A., Buffon, A., & Luca, G. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.011 · Cited by 179 · see citing works
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
Aliot, E., Capucci, A., Crijns, H. J. G. M., Goette, A., & Tamargo, J. L. (2010) · EP Europace · doi:10.1093/europace/euq382 · Cited by 168 · see citing works
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132 · see citing works
Drug-induced heart failure
Feenstra, J., Grobbee, D. E., Remme, W. J., & Stricker, B. H. C. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00006-6 · Cited by 111 · see citing works
Flecainide: Current status and perspectives in arrhythmia management
Andrikopoulos, G. K. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i2.76 · Cited by 102 · see citing works
European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS)
Boriani, G., Fauchier, L., Aguinaga, L., Beattie, J. M., Lundqvist, C. B., Cohen, A. A., Dan, G., Genovesi, S., Israel, C. W., Joung, B., et al. (2018) · EP Europace · doi:10.1093/europace/euy110 · Cited by 92 · see citing works
Atrial flutter: A review of its history, mechanisms, clinical features, and current therapy
LEE, K., Yang, Y., & Scheinman, M. M. (2005) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2004.07.001 · Cited by 81 · see citing works
Safely of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian study investigators
CHIMIENTI, M., The Flecainide and Propafenone Italian Study (FAPIS) Investigators, Cullen, M. T., & Casadei, G. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89119-9 · Cited by 78 · see citing works
Guías de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas
Garrote, J. A., Huerta, E. M., Moreno, O. M., Peinado, R., Álvarez, L. P., Granell, R. R., & Viñolas, X. (2001) · Revista Española de Cardiología · doi:10.1016/s0300-8932(01)76313-0 · Cited by 70 · see citing works
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a mmulticenter trial
Hopson, J. R., Buxton, A. E., Rinkenberger, R. L., Nademanee, K., Heilman, J. M., & Kienzle, M. G. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89121-7 · Cited by 54 · see citing works
Diagnosis and management of supraventricular tachycardia
Whinnett, Z. I., Sohaib, S. M. A., & Davies, D. W. (2012) · BMJ · doi:10.1136/bmj.e7769 · Cited by 47 · see citing works
Safety of Flecainide
Tamargo, J. L., Capucci, A., & Mabo, P. (2012) · Drug Safety · doi:10.2165/11599950-000000000-00000 · Cited by 46 · see citing works
JCS / JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Journal of Arrhythmia · doi:10.1002/joa3.12714 · Cited by 41 · see citing works
Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life
Guédon-Moreau, L., Capucci, A., Denjoy, I., Morgan, C. C., Perier, A., Leplège, A., & Kacet, S. (2010) · EP Europace · doi:10.1093/europace/euq007 · Cited by 43 · see citing works
Antiarrhythmic Drug Therapy in the Management of Atrial Fibrillation
Ganz, L. I., & Antman, E. M. (1997) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1997.tb01005.x · Cited by 38 · see citing works
Flecainide: Electrophysiological properties, clinical indications, and practical aspects
Paolini, E., Stronati, G., Guerra, F., & Capucci, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104443 · Cited by 30 · see citing works
Effectiveness of Verapamil-Quinidine Versus Digoxin-Quinidine in the Emergency Department Treatment of Paroxysmal Atrial Fibrillation
Innes, G. D., Vertesi, L., Dillon, E. C., & Metcalfe, C. (1997) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(97)70318-4 · Cited by 29 · see citing works
Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia
Malhamé, I., Gandhi, C., Tarabulsi, G., Esposito, M. A., Lombardi, K. C., Chu, A. F., & Chen, K. K. (2018) · Obstetric Medicine · doi:10.1177/1753495x18808118 · Cited by 28 · see citing works
Differential effects of dofetilide, amiodarone, and class Ic drugs on left and right atrial refractoriness and left atrial vulnerability in pigs
WIRTH, K. J., & Knobloch, K. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100000328 · Cited by 28 · see citing works
Supraventricular Tachycardia
Chauhan, V. S., Krahn, A. D., Klein, G. J., Skanes, A. C., & Yee, R. K. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70313-8 · Cited by 28 · see citing works
Flecainide acetate for the treatment of atrial and ventricular arrhythmias
Apostolakis, S. Z., Oeff, M., Tebbe, U., Fabritz, L., BREITHARDT, G. E., & Kirchhof, P. F. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.759212 · Cited by 25 · see citing works
Flecainide in clinical practice
Basza, M., Maciejewski, C., Bojanowicz, W., Balsam, P., Grabowski, M., Mitkowski, P. P., Kempa, M., Kowalski, O., Kalarus, Z. F., Jaguszewski, M. J., et al. (2023) · Cardiology Journal · doi:10.5603/cj.a2023.0018 · Cited by 22 · see citing works
Intravenous Administration of Magnesium and Potassium Solution Lowers Energy Levels and Increases Success Rates Electrically Cardioverting Atrial Fibrillation
Sultan, A., Steven, D., Rostock, T., Hoffmann, B. A., Müllerleile, K., Servatius, H., Drewitz, I., Lüker, J., Meyer, P., Salukhe, T. V., et al. (2011) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2011.02146.x · Cited by 22 · see citing works
CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Basta, M. N., MBBch, Klein, G. J., Yee, R. K., Krahn, A. D., & Lee, J. (1997) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70363-5 · Cited by 16 · see citing works
Probable Propafenone-Induced Transient Global Amnesia
Jones, R. J., Brace, S. R., & Tuin, E. L. V. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900606 · Cited by 14 · see citing works
Endocardial Mapping of Reentry Around an Anatomical Barrier in the Canine Right Atrium:
Pinto, J. M. B., Graziano, J. N., & Boyden, P. A. (1993) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1993.tb01253.x · Cited by 14 · see citing works
Flecainide-Induced Increase in QRS Duration and Proarrhythmia during Exercise
Bordier, P., Garrigue, S., Bernard, V., Haı̈ssaguerre, M., Douard, H., Broustet, J. P., & Clémenty, J. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199713060-00005 · Cited by 13 · see citing works
Safety and Efficacy of Oral Flecainide Acetate in Patients with Cardiac Arrhythmias.
Nakazato, Y., Nakata, Y., Yasuda, M., Nakazato, K., Sumiyoshi, M., Ogura, S., & Yamaguchi, H. (1997) · Japanese Heart Journal · doi:10.1536/ihj.38.379 · Cited by 13 · see citing works
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting
Kovacs, B., Yakupoglu, H. Y., Eriksson, U., Krasniqi, N., & Duru, F. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0116 · Cited by 12 · see citing works
2025 Clinical practice guidelines for Supraventricular tachycardias
Popov, S. V., Davtyan, K. V., Shubik, Y. V., Artyukhina, Е. А., Базаев, В. А., Batalov, R. E., Bokeria, L. A., Bubnova, M. G., Vygovsky, A. B., Sp, G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6448 · Cited by 12 · see citing works
Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients
Aliot, E., Roy, L. D., Capucci, A., Hernández, J. R. L., Denjoy, I., Lupoglazoff, J., & Coumel, P. (2003) · Annales de Cardiologie et d Angéiologie · doi:10.1016/s0003-3928(02)00183-x · Cited by 12 · see citing works
An Unusual Case of Flecainide‐induced QT Prolongation Leading to Cardiac Arrest
Oguayo, K. N., Oyetayo, O. O., Costa, S. M., & Mixon, T. A. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1403 · Cited by 11 · see citing works
Antiarrhythmic drug therapy of atrial fibrillation
Vernooy, R. A., & Mounsey, J. P. (2004) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00116-4 · Cited by 11 · see citing works
Use of medications in Wolff-Parkinson-White syndrome
Redfearn, D., Krahn, A. D., Skanes, A. C., Yee, R. K., & Klein, G. J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.6.955 · Cited by 10 · see citing works
Potent and Reversible Effects of ATI-2001 on Atrial and Atrioventricular Nodal Electrophysiological Properties in Guinea Pig Isolated Perfused Heart
Raatikainen, M. J. P., Morey, T. E., Druzgala, P. J., Milner, P., Gonzalez, M. D., & Dennis, D. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38968-2 · Cited by 10 · see citing works
To decide medical therapy according to ECG criteria in patients with supraventricular tachycardia in emergency department: adenosine or diltiazem.
Doğan, H., Özüçelik, D. N., Açıksarı, K., Çağlar, İ. M., Okutan, N., Yazicioglu, M., Avyaci, B. M., Simsek, C., Özaşır, D., Gıray, T. A., et al. (2015) · Europe PMC (PubMed Central) · Cited by 9 · see citing works
Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias
Katritsis, D. G., Boriani, G., Cosío, F. G., Jaı̈s, P., Hindricks, G., Josephson, M. E., Keegan, R., Knight, B. P., Kück, K., Lane, D. A., et al. (2016) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2016:5.3.gl1 · Cited by 7 · see citing works
Positive inotropic drugs and drugs used in dysrhythmias
Aronson, J. K. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80024-2 · Cited by 6 · see citing works
1:1 Atrioventricular conduction in atrial flutter with digoxin and flecainide
Ahsan, A., Aldridge, R., & Bowes, R. (1993) · International Journal of Cardiology · doi:10.1016/0167-5273(93)90301-v · Cited by 6 · see citing works
Effects of Procainamide on the Excitable Gap Composition in Common Human Atrial Flutter
Jalil, E., FRANC, P. L., Lebeau, R., Molin, F., Costi, P., & Kuś, T. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb00094.x · Cited by 6 · see citing works
Flecainide is effective against premature supraventricular and ventricular contractions during general anesthesia
Saishu, T., Iwatsuki, N., Tajima, T., & Hashimoto, Y. (1994) · Journal of Anesthesia · doi:10.1007/bf02514651 · Cited by 5 · see citing works
Atrial fibrillation management: evaluating rate vs rhythm control
Nguyen, T. L., Jolly, U. S., Sidhu, K., Yee, R. K., & Leong‐Sit, P. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1164033 · Cited by 4 · see citing works
Antiarrhythmic drugs part 2: rhythm-control drugs
Sampson, M. G. (2019) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2019.0067 · Cited by 4 · see citing works
Antiarrhythmic Drug Initiation for Atrial Fibrillation in the USA: How and Where
Newman, J., Strickberger, A., Spears, J., & Kowey, P. R. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16681 · Cited by 2 · see citing works
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmiasM — executive summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)
Alpert, J. S., Antman, E. M., Smith, S. C., Faxon, D. P., Fuster, V., Gibbons, R. J., Gregoratos, G., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., et al. (2003) · Cited by 2 · see citing works
Long-Term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm
Ganz, L. I., & Antman, E. M. (1997) · Cardiac Electrophysiology Review · doi:10.1023/a:1009955200266 · Cited by 2 · see citing works
Digoxin for the Management of Unstable Paroxysmal Supraventricular Tachycardia in a Patient Who Refused Electrical Cardioversion in a Rural Hospital
Kassa, B. D., Amede, M., Wubante, M., Libanos, M., & Geta, K. (2023) · Case Reports in Emergency Medicine · doi:10.1155/2023/7301460 · Cited by 1 · see citing works
Modern treatment of supraventricular tachycardia
Tarzimanova, A. I., & Podzolkov, V. I. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2694 · Cited by 1 · see citing works
Pharmakologische Therapie bei Vorhofflimmern – Was leisten moderne Antiarrhythmika wirklich?
Volkmann, H., Richter, L., & Bergmann, C. (2008) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-008-0034-z · Cited by 1 · see citing works
Tachycardie de la jonction auriculoventriculaire
Brembilla-Perrot, B. (2010) · EMC - Cardiologie · doi:10.1016/s1166-4568(10)53118-8 · Cited by 1 · see citing works
Conversion of Atrial Fibrillation: Pills, Shots, or Shocks?
Podrid, P. J. (1998) · Cardiac Electrophysiology Review · doi:10.1023/a:1009958911119 · Cited by 1 · see citing works
Focal atrial tachycardia Insights concerning the arrhythmogenic substrate based on analysis of intracardiac electrograms and inflammatory markers
Liuba, I. (2009) · DiVA (Linkoping University)
Bedeutung des autonomen Nervensystems bei paroxysmalem Vorhofflimmern
Hohnloser, S. H., van de Loo, A., & Zabel, M. (1994) · Steinkopff eBooks · doi:10.1007/978-3-642-93677-7_3
NaV1.5 Modulation: From Ionic Channels to Cardiac Conduction and Substrate Heterogeneity
Raad, N. (2014) · doi:10.53846/goediss-4436
Rate and Rhythm Control Strategies for Atrial Fibrillation
Yap, Y. G., & Camm, A. J. (2014) · doi:10.1007/978-1-907673-98-6_4
Pharmacological Therapy of Atrial Fibrillation and Flutter: Advances and Limitations of Specific Antiarrhythmic Drugs
Alboni, P. (2003) · Springer eBooks · doi:10.1007/978-88-470-2087-0_21
Supraventricular tachyarrhythmias that responded dramatically to bisoprolol transdermal patches in two patients undergoing hemodialysis
Matsumoto, T., Tamiya, E., Yamamoto, S., Kamiyama, T., Takabe, T., Kanoh, T., & Daida, H. (2019) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.12660
Positive inotropic drugs and drugs used in dysrhythmias
Aronson, J. K., & Derry, S. (1998) · Side effects of drugs annual · doi:10.1016/s0378-6080(98)80021-4
Flecainide
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/01376-0
Positive inotropic drugs and drugs used in dysrhythmias
Aronson, J. K. (1993) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80201-6
ANTIDYSRHYTHMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53268-8.50006-5
Flecainide
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00748-4
Supraventricular tachycardia pharmacotherapy in adults.
Owczarek, J., & Owczarek, W. (2022) · Farmacja Polska · doi:10.32383/farmpol/151593
Prophylaxis of Atrial Fibrillation: What are the Benefits and Risks of the Different Antiarrhythmic Drugs?
CHIMIENTI, M., & Barbieri, S. (1996) · Springer eBooks · doi:10.1007/978-88-470-2223-2_44

Summary of efficacy and safety of flecainide for supraventricular arrhythmias
Anderson, J. L., Jolivette, D. M., & Fredell, P. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90511-5 · Cited by 79 · see citing works
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a mmulticenter trial
Hopson, J. R., Buxton, A. E., Rinkenberger, R. L., Nademanee, K., Heilman, J. M., & Kienzle, M. G. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89121-7 · Cited by 54 · see citing works
Long-term efficacy and safety of flecainide for supraventricular tachycardia
Neuss, H., & Schlepper, M. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90509-7 · Cited by 21 · see citing works
Safety and Efficacy of Oral Flecainide Acetate in Patients with Cardiac Arrhythmias.
Nakazato, Y., Nakata, Y., Yasuda, M., Nakazato, K., Sumiyoshi, M., Ogura, S., & Yamaguchi, H. (1997) · Japanese Heart Journal · doi:10.1536/ihj.38.379 · Cited by 13 · see citing works
Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: The United States experience
Anderson, J. L., & The Flecainide Supraventricular Tachyarrhythmia Investigators (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91072-c · Cited by 37 · see citing works

Authors: Hohnloser, S. H., & Zabel, M.
Affiliations: University Medical Center Freiburg (DE)
Corresponding author: Hohnloser, Stefan H.
ORCID: Hohnloser, Stefan H.
Zabel, Markus
Venue: The American Journal of Cardiology
Publisher: Elsevier BV
Published: 1992-08
Volume: 70
Issue: 5
Pages: A3-A10
ISSN: 0002-9149 (ISSN-L)
DOI: 10.1016/0002-9149(92)91071-b
OpenAlex: W1964718370
Cited by: 74
References: 23
Citations by year: 2025: 2 · 2023: 2 · 2022: 4 · 2020: 1 · 2019: 4 · 2018: 2 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 1 · 2012: 2
FWCI: 2.56
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The American Journal of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: supraventricular arrhythmias, atrial fibrillation, atrial flutter, paroxysmal atrial fibrillation, atrioventricular reciprocating tachycardia, atrioventricular nodal reentrant tachycardia, Wolff-Parkinson-White syndrome, ectopic atrial tachycardia, antiarrhythmic efficacy, drug safety, drug-induced arrhythmia, adverse drug reactions, long-term treatment, quality of life
MeSH terms: Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Flecainide, Humans, Risk Factors, Tachycardia, Supraventricular, Wolff-Parkinson-White Syndrome, Meta-Analysis as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks